阿尔茨海默病突触丢失的[18F]UCB-H PET在体显像
患者多个皮层区及丘脑摄取下降,海马下降最显著达31%,且海马摄取降低与认知减退及记忆问题无觉察相关。
要点
- 患者皮层区[18F]UCB-H摄取较对照下降11%至18%,丘脑下降16%。
- 海马摄取下降最显著,达31%,效应量最大。
- 海马摄取降低与患者认知减退及记忆问题无觉察相关。
核心结论
- 阿尔茨海默病以海马突触丢失为主,[18F]UCB-H PET可在体显像突触改变并与认知损害相关。
研究设计与样本
- 用Logan图形分析结合图像衍生血输入函数定量[18F]UCB-H脑摄取。
- 采用SPM12和感兴趣区分析比较脑区分布容积并与认知指标相关。
主要发现
- 多个皮层区[18F]UCB-H摄取显著下降,差异11%至18%。
- 丘脑摄取下降16%,海马效应量最大,差异31%。
- 海马摄取降低与患者认知减退相关(ROI分析)。
- 海马摄取降低与记忆问题无觉察相关(SPM和ROI分析)。
临床怎么用
- [18F]UCB-H PET可用于在体评估阿尔茨海默病突触丢失并与认知损害关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Loss of brain synapses is an early pathological feature of Alzheimer's disease. The current study assessed synaptic loss in vivo with positron emission tomography and an 18F-labelled radiotracer of the synaptic vesicle protein 2A, [18F]UCB-H. METHODS: Twenty-four patients with mild cognitive impairment or Alzheimer's disease and positive [18F]Flutemetamol amyloid-PET were compared to 19 healthy controls. [18F]UCB-H brain uptake was quantified with Logan graphical analysis using an image-derived blood input function. SPM12 and regions-of-interest (ROI) analyses were used for group comparisons of regional brain distribution volumes and for correlation with cognitive measures. RESULTS: A significant decrease of [18F]UCB-H uptake was observed in several cortical areas (11 to 18% difference) and in the thalamus (16% difference), with the largest effect size in the hippocampus (31% difference). Reduced hippocampal uptake was related to patients' cognitive decline (ROI analysis) and unawareness of memory problems (SPM and ROI analyses). CONCLUSIONS: The findings thus highlight predominant synaptic loss in the hippocampus, confirming previous autopsy-based studies and a recent PET study with an 11C-labelled SV2A radiotracer. [18F]UCB-H PET allows to image in vivo synaptic changes in Alzheimer's disease and to relate them to patients' cognitive impairment.
引用
- Bastin C, Bahri MA, Meyer F, et al. In vivo imaging of synaptic loss in Alzheimer's disease with [18F]UCB-H positron emission tomography. Eur J Nucl Med Mol Imaging. 2019. PMID: 31468182. doi:10.1007/s00259-019-04461-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。